Patents by Inventor Jeff Zablocki

Jeff Zablocki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210115037
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 22, 2021
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
  • Publication number: 20200171020
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Application
    Filed: October 30, 2019
    Publication date: June 4, 2020
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
  • Patent number: 10640499
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 5, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Patent number: 10603318
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 31, 2020
    Assignee: Gilead Pharmasset LLC
    Inventors: Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Kyla Ramey, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • Publication number: 20200017451
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Application
    Filed: June 14, 2019
    Publication date: January 16, 2020
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Patent number: 10507215
    Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: December 17, 2019
    Assignee: Amygdala Neurosciences, Inc.
    Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
  • Publication number: 20190365748
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Application
    Filed: May 10, 2019
    Publication date: December 5, 2019
    Inventors: Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Kyla Ramey, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • Publication number: 20190282576
    Abstract: The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
    Type: Application
    Filed: January 22, 2019
    Publication date: September 19, 2019
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-Jung Pyun, Jeff Zablocki
  • Patent number: 10370342
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 6, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Patent number: 10335409
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: July 2, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • Patent number: 10285990
    Abstract: The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: May 14, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-Jung Pyun, Jeff Zablocki
  • Patent number: 10259811
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: April 16, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Juan Arnaldo Guerrero, Joshua Aaron Kaplan, John Edward Knox, Jr., Devan Naduthambi, Barton W. Phillips, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jeff Zablocki
  • Publication number: 20190016717
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Application
    Filed: July 24, 2018
    Publication date: January 17, 2019
    Inventors: Zhimin DU, Juan Arnaldo GUERRERO, Joshua Aaron KAPLAN, John Edward KNOX, JR., Devan NADUTHAMBI, Barton W. PHILLIPS, Chandrasekar VENKATARAMANI, Peiyuan WANG, William J. WATKINS, Jeff ZABLOCKI
  • Publication number: 20190008858
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Application
    Filed: June 11, 2018
    Publication date: January 10, 2019
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • Publication number: 20180338989
    Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 29, 2018
    Applicant: Amygdala Neurosciences, Inc.
    Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
  • Patent number: 10100058
    Abstract: The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R1, R2, R3, R4, R5, R6, R9 and R10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: October 16, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry, Scott Preston Simonovich, Jeff Zablocki, Christopher Allen Ziebenhaus
  • Publication number: 20180282316
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna M. Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick Andrew Lee, Ruben Martinez, Samuel E. Metobo, Michael R. Mish, Manuel Munoz, Sophia L. Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Patent number: RE47301
    Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: March 19, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Robert Seemayer, Travis Lemons
  • Patent number: RE47351
    Abstract: N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: April 16, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli
  • Patent number: RE48150
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, R, R1, R2 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: August 11, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Gregory Notte, Jeff Zablocki